阿卡波糖治疗精神分裂症伴糖耐量减低的随机对照研究  

Acarbose in the treatment of schizophrenia with impaired glucose tolerance:a random-control study

作　　者：陈琪[1] 宋梓祥[1] 纪菊英[1] 汪莉[1] 施辉[1] 孙剑[1] 

机构地区：[1]解放军第102医院精神二科,江苏常州213003

出　　处：《精神医学杂志》2008年第2期101-102,共2页Journal of Psychiatry

摘　　要：目的探讨阿卡波糖治疗精神分裂症患者伴发糖耐量减低的疗效与不良反应。方法选取60例糖耐量减低的精神分裂症患者,随机分为2组,分别接受阿卡波糖(阿卡波糖组)、二甲双胍(二甲双胍组)治疗,疗程4周。检测治疗前、治疗后4周空腹血糖(FPG)、糖耐量试验2小时血糖值(2HPG)及糖化血红蛋白(HbAlc)。结果两组治疗后FPG、2HPG及HbAlc较治疗前均显著下降(P<0.05);阿卡波糖组治疗后2HPG较二甲双胍组下降显著(P<0.05),而治疗后FPG、HbAlc则与二甲双胍组无显著差异(P>0.05);两组不良反应发生率相近。结论阿卡波糖可用于临床治疗精神分裂症伴发糖耐量减低。Objective To investigate the efficacy and side effects of acarbose in the treatment of schizophrenia with impaired glucose tolerance. Methods Sixty schizophrenia were randomly divided into two groups treated with acarbose or metformin respectively for treatment of 4 weeks. The fasting plasma glucose（FPG）, 2-hour plasma glucose tolerance test （2HPG） and glycated hemoglobin AIC （HbAlc） were measured before and after treatment. Results FPG,2HPG and HbAlc had significantly reduced in two groups after 4-week treatment（P 〈0.05）. After treatment,2HPG had significantly more reduced in acarbose group than metformin group （P〈 0.05）, and no significant differences were found in the FPG and HbAlc between two groups （P〉0.05）. The prevalence of side effects were similar in two groups. Conclusion Acarbose is an effective drug in the treatment of impaired glucose tolerance in schizophrenia.

关 键 词：阿卡波糖 精神分裂症 糖耐量减低 

分 类 号：R749.3[医药卫生—神经病学与精神病学]